Rebecca Grochowski, NP
Gerontology · Towson, MDNPI 1861046567
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,566 of the $3,081 with a category attached, or 83.3%. It is spread thinly across 26 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,219 and has fallen 58.3% since, to $508 in 2025. Among gerontology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 111 payments — averaging $27.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$472
- Johnson & Johnson$467
- Incyte Corporation$343
- E.r. Squibb & Sons, L.L.C.$204
- GSK$202
- AbbVie$197
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,56683%
- Education$51617%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 17 | $472 |
| Johnson & Johnson | 15 | $467 |
| Incyte Corporation | 10 | $343 |
| E.r. Squibb & Sons, L.L.C. | 9 | $204 |
| GSK | 9 | $202 |
| AbbVie(2 entities) | 7 | $197 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $167 |
| Lilly USA, LLC | 2 | $139 |
| Novartis | 3 | $86 |
| Merck | 3 | $71 |
| Genentech USA, Inc. | 3 | $66 |
| Seagen Inc. | 3 | $65 |
| Astellas Pharma US Inc | 3 | $65 |
| Pfizer | 3 | $64 |
| Beigene USA, Inc. | 2 | $62 |
| Hologic Sales And Service, LLC | 1 | $59 |
| Daiichi Sankyo Inc. | 2 | $57 |
| Eisai Inc. | 2 | $56 |
| Stemline Therapeutics Inc. | 2 | $44 |
| Mirati Therapeutics, Inc. | 2 | $43 |
| Jazz Pharmaceuticals Inc. | 2 | $38 |
| Immunogen, Inc. | 1 | $28 |
| Gilead | 1 | $24 |
| Exelixis Inc. | 1 | $23 |
| Blueprint Medicines Corporation | 1 | $23 |
| Amgen | 1 | $16 |
How this compares
$3,081 in reported general payments places this provider in the 90th percentile of 108 gerontology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 31 | $455,913 |
| PomalystPomalidomide | 18 | $373,373 |
| ImbruvicaIbrutinib | 15 | $234,672 |
| JakafiRuxolitinib Phosphate | 11 | $218,638 |
| SprycelDasatinib | 14 | $157,787 |
| NyvepriaPegfilgrastim-Apgf | 11 | $41,215 |
| EliquisApixaban | 30 | $29,976 |
| XareltoRivaroxaban | 18 | $18,496 |
| Exemestane | 32 | $5,962 |
| Letrozole | 64 | $1,653 |
| Anastrozole | 36 | $1,073 |
| Tamoxifen Citrate | 24 | $726 |
| Potassium Chloride | 24 | $514 |
| Prochlorperazine Maleate | 19 | $420 |
| Hydroxyurea | 13 | $377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $204 | $531,16032 claims |
| Lilly USA, LLCVerzenio | $139 | $455,91331 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $167 | $234,67215 claims |
| Incyte CorporationJakafi | $343 | $218,63811 claims |
| PfizerNyvepria, Eliquis | $64 | $71,19041 claims |
| Johnson & JohnsonXarelto | $467 | $18,49618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 108 gerontology providers in Maryland.
Other gerontology in Towson
- Valdane RobinsonTowson$10K
- Christi DieterichElkridge$15K
- Megan GessfordLeonardtown$12K
- Victoria SinibaldiBaltimore$10K
- Angeline WilliamsCatonsville$6K
- Wingnay CherneskyParkville$5K
- Joyce LamWaldorf$4K
- Eyerusalem HagosEssex$4K
- Diana NgOlney$3K
- Emily HanBaltimore$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.